Laxatives and Purgatives: Mechanisms and 2023 AGA–ACG Constipation Guidelines

Medical education review — 10 November 2026. Not a substitute for individualized diagnosis, prescribing advice or local guidance.

Overview

Constipation may reflect slow colonic transit, pelvic-floor dysfunction, medications or systemic illness. Initial assessment should identify alarm features such as rectal bleeding, anemia, unexplained weight loss, severe progressive pain or obstruction before recommending chronic laxative use [1, 2].

Accurate pharmacological classification

  • Bulk-forming fiber: psyllium increases stool water retention and bulk; adequate fluids matter and it may worsen symptoms with significant obstruction or dysphagia.
  • Osmotic agents: polyethylene glycol (PEG), lactulose, magnesium oxide and selected magnesium salts draw water into the lumen; magnesium requires caution in kidney impairment.
  • Stimulant laxatives: bisacodyl, sodium picosulfate and senna increase colonic secretion and motility. These are not ‘sedative laxatives’ or ‘metabolic inhibitors.’
  • Intestinal secretagogues: linaclotide and plecanatide activate guanylate cyclase-C; lubiprostone activates chloride transport through epithelial pathways.
  • 5-HT4 agonist: prucalopride enhances propulsive colonic motor activity.
  • Lubricants/softeners: mineral oil and docusate have limited roles and require patient-specific caution.
  • Peripherally acting μ-opioid receptor antagonists: naloxegol, naldemedine and methylnaltrexone for selected opioid-induced constipation, not primary idiopathic constipation.

Evidence-based chronic constipation treatment

The joint 2023 AGA–ACG guideline strongly recommends PEG for chronic idiopathic constipation in adults. It also strongly recommends linaclotide, plecanatide and prucalopride after inadequate response to OTC therapies, as well as bisacodyl or sodium picosulfate for short-term or rescue use. Fiber, magnesium oxide, lactulose, senna and lubiprostone carry conditional recommendations in specified settings. The sequence should reflect response, cost, contraindications and patient preference [2].

Pharmacokinetics and administration

PEG acts mostly within the lumen and is minimally absorbed; lactulose is fermented by colonic bacteria. Linaclotide has minimal systemic absorption and may cause diarrhea. Prucalopride is systemically absorbed and predominantly renally excreted, requiring consideration of kidney function. Do not combine multiple agents routinely without assessment of hydration, electrolytes and obstruction risk [1, 2].

Safety and special populations

Overuse can cause diarrhea, dehydration and electrolyte abnormalities. Bulk agents require adequate fluid intake; mineral oil can cause aspiration-related lipoid pneumonia and interfere with fat-soluble vitamin absorption. Avoid phosphate-containing bowel preparations or enemas in vulnerable patients without professional guidance because of acute phosphate nephropathy and electrolyte disturbances. Pediatric and pregnancy management differ from adult chronic idiopathic constipation recommendations [1, 2].

Purgatives and bowel preparation

High-volume or split-dose PEG-electrolyte preparations and selected approved alternatives are used for colonoscopy cleansing under endoscopy-specific protocols; they should not be confused with routine maintenance treatment. Patients with kidney disease, heart failure or electrolyte instability need an individualized preparation plan [1].

Timing a colonoscopy preparation

A daily maintenance laxative aims for comfortable, regular defecation. Colonoscopy preparation requires sufficient cleansing for inspection of the entire mucosa. Follow the endoscopy unit’s instructions for the prescribed preparation, timing and fluid intake. US Multi-Society Task Force guidance recommends split dosing, with a portion taken on the day of examination. A same-day regimen is an acceptable option for an afternoon procedure. The timing of the last dose matters because new intestinal contents can obscure the mucosa between preparation and examination. [3]

Clinical takeaways

Treat the cause where possible, optimize dietary fiber and activity if appropriate, review constipating medicines and investigate pelvic-floor dysfunction when suggested by history or treatment failure. Stimulants are not secretagogues, and bile acid sequestrants generally treat diarrhea rather than routine constipation [1, 2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. American Gastroenterological Association and American College of Gastroenterology. Pharmacological management of chronic idiopathic constipation. 2023 May 19. Available from: https://gastro.org/clinical-guidance/pharmacological-management-of-chronic-idiopathic-constipation-cic/
  3. US Multi-Society Task Force on Colorectal Cancer. Optimizing bowel preparation quality for colonoscopy: consensus recommendations. 2025. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *